PT-141

FDA Approved

Bremelanotide

Also known as Bremelanotide, PT-141 is an FDA-approved peptide for sexual dysfunction. It works centrally in the brain rather than on the vascular system like traditional treatments.

SubQ injectionNasal spraySexual HealthReproductive Health

Dose

0.75 mg to 1.75 mg

Route

SubQ injection, Nasal spray

Cycle

N/A

Storage

Refrigerated (2°C to 8°C / 36°F to 46°F)

What is PT-141?

PT-141, also known as Bremelanotide, is a synthetic peptide derived from the melanocortin peptide family. Unlike traditional treatments for sexual dysfunction that target the vascular system, PT-141 acts centrally in the brain by agonizing melanocortin 4 receptors (MC4R). This mechanism is thought to stimulate a natural sexual response pathway, leading to increased libido and arousal in both men and women. It is commonly discussed in research for its potential use in hypoactive sexual desire disorder (HSDD) and erectile dysfunction, particularly in individuals who may not respond to phosphodiesterase-5 (PDE5) inhibitors.

Key Benefits

Increased libido
Sexual arousal
Improved erectile function
Works for both men and women
Alternative for those unresponsive to PDE5 inhibitors

Mechanism of Action

Melanocortin 4 receptor agonist
Acts centrally in brain to stimulate sexual desire
Does not affect vascular system directly

Best For

Sexual health research
Libido research

Body Systems

Nervous SystemReproductiveEndocrine

🐾 Griffin Says...

FDA approved for HSDD (hypoactive sexual desire disorder) in premenopausal women. Also researched for men who don't respond to Viagra. Works differently from other sexual health treatments since it acts on the brain, not blood vessels.

Molecular Information

Molecular weight

1023.2 g/mol

Length

7 amino acids

Type

Cyclic heptapeptide

Amino acid sequence

Ac-Nle-cyclo(Asp-His-D-Phe-Arg-Trp-Lys)-OH

Acetyl-Norleucyl-cyclo(Aspartyl-Histidyl-D-Phenylalanyl-Arginyl-Tryptophyl-Lysyl)-OH

Pharmacokinetics

Time to peak

Approximately 1 hour

Half-life

2.7 h

Time to clear

Elimination takes several hours, with most cleared within 24 hours.

DoseEstimated plasma concentration16 h

Frohlich, P., & Meston, C. M. (2020). The pharmacokinetics of bremelanotide in healthy premenopausal women and men. Sexual Medicine, 8(1), 127-133.

Research Indications

Female Sexual Dysfunction (FSD)
Studies indicate efficacy in improving desire and arousal in premenopausal women with hypoactive sexual desire disorder (HSDD).
Erectile Dysfunction (ED)
Research suggests potential for improving erectile function, especially in men unresponsive to PDE5 inhibitors, by acting on central pathways.

Research Protocols

Goal	Dose	Frequency	Route
Assess efficacy in premenopausal women with HSDD (SubQ)	1.75 mg	As needed, not more than once every 24 hours and not more than 8 doses per month	Subcutaneous injection
Evaluate safety and tolerability in men with ED (SubQ)	1.25 mg to 1.75 mg	As needed, not more than once every 24 hours and not more than 8 doses per month	Subcutaneous injection
Pharmacokinetic and Pharmacodynamic studies (SubQ)	0.75 mg to 1.75 mg	Single dose or spaced doses according to study design	Subcutaneous injection
Exploratory studies via intranasal administration	1.75 mg to 10 mg (variable, often higher due to bioavailability)	As needed	Intranasal

The timing of administration is critical for maximizing its intended effects related to sexual activity.

Peptide Interactions

PDE5 Inhibitors (e.g., Sildenafil, Tadalafil)
PT-141 acts via a different mechanism (central nervous system) than PDE5 inhibitors (vascular system). Some research protocols have explored co-administration, noting no direct contraindication but careful monitoring is advised.
Compatible
Alcohol
While no specific contraindication exists, alcohol can impair sexual function and may mask or enhance side effects like nausea or dizziness. Moderation is commonly advised.
Monitor Combination
Opioids
Opioids can suppress sexual desire. PT-141's efficacy may be reduced, and the combination could potentially alter central nervous system effects. Monitoring for altered response is suggested.
Use Caution
Blood Pressure Medications
PT-141 can cause transient increases or decreases in blood pressure. Individuals on antihypertensive or hypotensive medications should be monitored closely for significant blood pressure fluctuations.
Use Caution

How to Reconstitute

1Gather supplies: PT-141 vial, bacteriostatic water for injection, sterile syringe with needle, alcohol wipes.
2Remove the plastic cap from the PT-141 vial and wipe the rubber stopper with an alcohol wipe.
3Wipe the top of the bacteriostatic water vial with a new alcohol wipe.
4Draw the desired amount of bacteriostatic water into the syringe (e.g., 1-2 mL for a typical vial size).
5Slowly inject the bacteriostatic water into the PT-141 vial, directing the stream down the side of the vial to avoid direct contact with the peptide powder.
6Do not shake the vial. Gently swirl the vial to allow the peptide to fully dissolve. This may take a few minutes.

Reconstitution should be performed using bacteriostatic water for injection. Proper aseptic technique is crucial to maintain sterility.

What to Expect

Within 1-2 hours of administration, some individuals may report increased feelings of sexual desire or arousal.
Effects are generally transient, lasting for several hours following administration.
Reductions in sexual dysfunction symptoms may be observed on an 'as-needed' basis.
Potential side effects such as flushing, headache, nausea, and injection site reactions are commonly reported in research.
Consistency in response can vary between individuals and across different administrations.

Side Effects & Safety

Effect	Frequency	Severity
Nausea	Common	Mild
Facial flushing	Common	Mild
Headache	Common	Mild
Temporary blood pressure changes	Uncommon	Moderate

Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾

Open Calculator

Peptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.